重磅!1.8万字回顾过去10年胃肠病学和肝病学关键突破
1.Binmoeller KF. Shah J A novel lumen-apposing stent for transluminal drainage of nonadherent extraintestinal fluid collections. Endoscopy 2011;43:337–42.
2. US Food and Drug Administration. De novo classification request for Xlumena axios stent and delivery system. (https://www.accessdata.fda. gov/cdrh_docs/reviews/K123250.pdf). Accessed June 17, 2020.
3. US Department of Health & Human Services. (https://www.accessdata. fda.gov/cdrh_docs/pdf16/K163272.pdf). Accessed February 28, 2020.
4. Itoi T, Binmoeller KF, Shah J, et al. Clinical evaluation of a novel lumenapposing metal stent for endosonography-guided pancreatic pseudocyst and gallbladder drainage (with videos). Gastrointest Endosc 2012;75: 870–6.
5. Itoi T, Binmoeller KF. EUS-guided choledochoduodenostomy using a biflanged lumen-apposing metal stent (with video). Gastrointest Endosc 2014;79:715.
6. Barthet M, Binmoeller KF, Vanbiervliet G, et al. Natural orifice transluminal endoscopic surgery gastroenterostomy with a biflanged lumen-apposing stent: First clinical experience (with videos). Gastrointest Endosc 2015;81:215–8.
7. Kedia P, Kumta N, Sharaiha R, et al. Bypassing the bypass: Endoscopic ultrasound-directed transgastric ERCP (EDGE) for Roux-en-Y anatomy. Gastrointest Endosc 2014;81:223–4.
8. Sumiyama K, Gostout CJ, Rajan E, et al. Submucosal endoscopy with mucosal flap safety valve. Gastrointest Endosc 2007;65:688–94.
9. Pasricha PJ, Hawari R, Ahmed I, et al. Submucosal endoscopic esophageal myotomy: A novel experimental approach for the treatment of achalasia. Endoscopy 2007;39:761–4.
10. Inoue H, Minami H, Kobayashi Y, et al. Peroral endoscopic myotomy (POEM) for esophageal achalasia. Endoscopy 2010;42:265–71.
11. Xu MD, Cai MY, Zhou PH, et al. Submucosal tunneling endoscopic resection: A new technique for treating upper GI submucosal tumors originating from the muscularis propria layer (with videos). Gastrointest Endosc 2012;75:195–9.
12. Khashab MA, Stein E, Clarke JO, et al. Gastric peroral endoscopic myotomy for refractory gastroparesis: First human endoscopic pyloromyotomy (with video). Gastrointest Endosc 2013;78:764–8.
13. Li QL, Chen WF, Zhang XC, et al. Submucosal tunneling endoscopic septum division: A novel technique for treating Zenker’s diverticulum. Gastroenterology 2016;151:1071–4.
14. Inoue H, Sato H, Ikeda H, et al. Peroral endoscopic myotomy:A series of 500 patients. J Am Coll Surg 2015;221:256–64.
15. Teitelbaum EN, Dunst CM, Reavis KM, et al. Clinical outcomes five years after POEM for treatment of primary esophageal motility disorders. Surg Endosc 2018;32:421–7.
16. Li QL, Wu QN, Zhang XC, et al. Outcomes of peroral endoscopic myotomy for treatment of esophageal achalasia with amedian followup of 49 months. Gastrointest Endosc 2018;87:1405–12.
17. Dacha S, Wang L, Xiaoyu L, et al. Outcomes and quality of life assessment after per oral endoscopic myotomy (POEM) performed in the endoscopy unit with trainees. Surg Endosc 2018;32:3046–54.
18. Chen T, Zhang C, Yao LQ, et al. Management of the complications of submucosal tunneling endoscopic resection for upper gastrointestinal submucosal tumors. Endoscopy 2016;48:149–55.
19. Ye LP, Zhang Y, Mao XL, et al. Submucosal tunneling endoscopic resection for small upper gastrointestinal subepithelial tumors originating from the muscularis propria layer. Surg Endosc 2014;28: 524–30.
20. Chen HM, Li BW, Li LY, et al. Current status of endoscopic resection of gastric subepithelial tumors. Amer J Gastroenterol 2019;114:718–25.
21. Khashab MA, Ngamruengphong S, Carr-Locke D, et al. Gastric peroral endoscopic myotomy for refractory gastroparesis: Results from the first multicenter study on endoscopic pyloromyotomy (with video). Gastrointest Endosc 2017;85:123–8.
22. Gonzalez JM, Lestelle V, Benezech A, et al. Gastric peroral endoscopic myotomy with antropyloromyotomy in the treatment of refractory gastroparesis: Clinical experience with follow-up and scintigraphic evaluation (with video). Gastrointest Endosc 2017;85:132–9.
23. Dacha S, Mekaroonkamol P, Li L, et al. Outcomes and quality-of-life assessment after gastric peroral endoscopic pyloromyotomy (with video). Gastrointest Endosc 2017;86:282–9.
24. Albers DV, Kondo A, Bernardo WM, et al. Endoscopic versus surgical approach in the treatment of Zenker’s diverticulum: Systematic review and meta-analysis. Endosc Int Open 2016;4:E678–86.
25. Ishaq S, Hassan C, Antonello A, et al. Flexible endoscopic treatment for Zenker’s diverticulum: A systematic review and meta-analysis. Gastrointest Endosc 2016;83:1076–89.
26. Hirao M, Masuda K, Asanuma T, et al. Endoscopic resection of early gastric cancer and other tumors with local injection of hypertonic salineepinephrine. Gastrointest Endosc 1988;34:264–9.
27. Chen H, Li B, Li L, et al. Current status of endoscopic resection of gastric subepithelial tumors. Am J Gastroenterol 2019;114:718–25.
28. Verfaillie CJ, Bruno MJ, Voor in ’t Holt AF, et al. Withdrawal of a noveldesign duodenoscope ends outbreak of a VIM-2-producing Pseudomonas aeruginosa [published correction appears in Endoscopy. 2015 Jun;47(6):502]. Endoscopy 2015;47:493–502.
29. Epstein L, Hunter JC, Arwady MA, et al. New Delhi metallob- lactamase-producing carbapenem-resistant Escherichia coli associated with exposure to duodenoscopes. JAMA 2014;312:1447–55.
30. Humphries RM, Yang S, Kim S, et al. Duodenoscope-related outbreak of a carbapenem-resistant Klebsiella pneumoniae identified using advanced molecular diagnostics. Clin Infect Dis 2017;65:1159–66.
31. Rubin ZA, Kim S, Thaker AM, et al. Safely reprocessing duodenoscopes: Current evidence and future directions. Lancet Gastroenterol Hepatol 2018;3:499–508.
32. (http://wayback.archive-it.org/7993/20170722150658/https://www.fda. gov/MedicalDevices/Safety/AlertsandNotices/ucm454766.htm). Accessed February 28, 2020.
33. Snyder GM, Wright SB, Smithey A, et al. Randomized comparison of 3 high-level disinfection and sterilization procedures for duodenoscopes. Gastroenterology 2017;153:1018–25.
34. Bartles RL, Leggett JE, Hove S, et al. A randomized trial of single versus double high-level disinfection of duodenoscopes and linear echoendoscopes using standard automated reprocessing. Gastrointest Endosc 2018;88:306–13.e2.
35. (https://www.fda.gov/media/132346/download). Accessed February 28, 2020.
36. (https://www.fda.gov/medical-devices/safety-communications/fdarecommending- transition-duodenoscopes-innovative-designsenhance- safety-fda-safety-communication). Accessed February 28, 2020.
37. Ross AS, Bruno MJ, Kozarek RA, et al. Novel single-use duodenoscope compared with 3 models of reusable duodenoscopes for ERCP: A randomized bench-model comparison. Gastrointest Endosc 2020;91: 396–403.
38. Muthusamy VR, Bruno MJ, Kozarek RA, et al. Clinical evaluation of a single-use duodenoscope for endoscopic retrograde cholangiopancreatography [published online ahead of print, 2019 Nov 6]. Clin Gastroenterol Hepatol 2019;S1542–3565(19):31261–3.
39. Lee JK, Merchant SA, Schneider JL, et al. Proton pump inhibitor use and risk of gastric, colorectal, liver, and pancreatic cancers in a communitybased population. Am J Gastroenterol 2020;115:706–15.
40. Kurlander JE, Kennedy JK, Rubenstein JH, et al. Patients’ perceptions of proton pump inhibitor risks and attempts at discontinuation:A national Survey. Am J Gastroenterol 2019;114:244–9.
41. Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: Expert review and best practice advice from the American Gastroenterological Association. Gastroenterology 2017; 152:706–15.
42. Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology 2019;157:682–91.e2.
43. Kinoshita Y, Ishimura N, Ishihara S. Management of GERD: Are potassium-competitive acid blockers superior to proton pump inhibitors? Am J Gastroenterol 2018;113:1417–9.
44. Patel A, Sayuk GS, Gyawali CP. Parameters on esophageal pHimpedance monitoring that predict outcomes of patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2015;13: 884–91.
45. Gyawali CP, Kahrilas PJ, Savarino E, et al. Modern diagnosis of GERD: The Lyon consensus. Gut 2018;67:1351–62.
46. Frazzoni M, de BortoliN, Frazzoni L, et al. The added diagnostic value of postreflux swallow-induced peristaltic wave index and nocturnal baseline impedance in refractory reflux disease studied with ontherapy impedance-pH monitoring. Neurogastroenterol Motil 2017;29; (doi:10.1111/nmo.12947).
47. Frazzoni M, Savarino E, de Bortoli N, et al. Analyses of the post-reflux swallow-induced peristaltic wave index and nocturnal baseline impedance parameters increase the diagnostic yield of impedance-pH monitoring of patients with reflux disease. Clin Gastroenterol Hepatol 2016;14:40–6.
48. Martinucci I, de Bortoli N, Savarino E, et al. Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn. Neurogastroenterol Motil 2014;26:546–55.
49. Ates F, Yuksel ES, Higginbotham T, et al. Mucosal impedance discriminates GERD from non-GERD conditions. Gastroenterology 2015;148:334–43.
50. Patel DA, Higginbotham T, Slaughter JC, et al. Development and validation of a mucosal impedance contour analysis systemto distinguish esophageal disorders. Gastroenterology 2019;156:1617–26.e1.
51. Spechler SJ, Hunter JG, Jones KM, et al. Randomized trial of medical versus surgical treatment for refractory heartburn. N Engl J Med 2019; 381:1513–23.
52. Patel A, Sayuk GS, Gyawali CP. Acid-based parameters on pHimpedance testing predict symptom improvement with medical management better than impedance parameters. Am J Gastroenterol 2014;109:836–44.
53. Patel A, Sayuk GS, Kushnir VM, et al. GERD phenotypes from pHimpedance monitoring predict symptomatic outcomes on prospective evaluation. Neurogastroenterol Motil 2016;28:513–21.
54. Bell R, Lipham J, Louie B, et al. Laparoscopic magnetic sphincter augmentation versus double-dose proton pump inhibitors for management of moderate-to-severe regurgitation in GERD: A randomized controlled trial. Gastrointest Endosc 2019;89:14–22.e1.
55. Bell R, Lipham J, Louie BE, et al. Magnetic sphincter augmentation superior to proton pump inhibitors for regurgitation in a 1-year randomized trial. Clin Gastroenterol Hepatol 2019;10:S1542–3565; (doi: 10.1016/j.cgh.2019.08.056).
56. Hunter JG, Kahrilas PJ, Bell RC, et al. Efficacy of transoral fundoplication vs omeprazole for treatment of regurgitation in a randomized controlled trial. Gastroenterology 2015;148:324–33.e5.
57. Shaheen NJ, Falk GW, Iyer PG, et al. American College of Gastroenterology clinical guideline: Diagnosis and management of Barrett’s esophagus. Am J Gastroenterol 2016;111:30–50.
58. Jankowski JAZ, de Caestecker J, Love SB, et al. Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): A randomised factorial trial. The Lancet 2018;392:400–8.
59. Chen MJ, Chen CC, Chen YN, et al. Systematic review with metaanalysis: Concomitant therapy vs. triple therapy for the first-line treatment of Helicobacter pylori infection. Am J Gastroenterol 2018; 113:1444–14576.
60. Sonnenberg A, Turner KO, Genta RM. Low prevalence of Helicobacter pylori-positive peptic ulcers in private outpatient endoscopy centers in the United States. Am J Gastroenterol 2020;115:244–50.
61. Tan MC, Mallepally N, Liu Y, et al. Demographic and lifestyle risk factors for gastric intestinal metaplasia among US Veterans. Am J Gastroenterol 2020;115:381–7.
62. Kaji K, Hashiba A, Uotani C, et al. Grading of atrophic gastritis is useful for risk stratification in endoscopic screening for gastric cancer. Am J Gastroenterol 2019;114:71–9.
63. Talley NJ, Walker MM. The rise and rise of eosinophilic gut diseases including eosinophilic esophagitis is probably not explained by the disappearance of Helicobacter pylori, so who or what’s to blame? Am J Gastroenterol 2018;113:941–4.
64. Dellon ES, Speck O, Woodward K, et al. Clinical and endoscopic characteristics do not reliably differentiate PPI-responsive esophageal eosinophilia and eosinophilic esophagitis in patients undergoing upper endoscopy: A prospective cohort study. Am J Gastroenterol 2013;108: 1854–60.
65. Moawad FJ, Veerappan GR, Dias JA, et al. Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia. Am J Gastroenterol 2013;108:366–72.
66. Molina-Infante J, Lucendo AJ. Proton pump inhibitor therapy for eosinophilic esophagitis: A paradigm shift. Am J Gastroenterol 2017; 112:1770–3.
67. Lucendo AJ, Molina-Infante J, Arias A, et al. Guidelines on eosinophilic esophagitis: Evidence-based statements and recommendations for diagnosis and management in children and adults. United Eur Gastroenterol J 2017;5:335–58.
68. Straumann A, Hoesli S, Bussmann C, et al. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy 2013;68:375–85.
69. Dellon ES, Katzka DA, Collins MH, et al. Budesonide oral suspension improves symptomatic, endoscopic, and histologic parameters compared with placebo in patients with eosinophilic esophagitis. Gastroenterology 2017;152:776–86.e5.
70. Hirano I, CollinsMH,Assouline-Dayan Y, et al. RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis. Gastroenterology 2019;156: 592–603.e10.
71. Lucendo AJ, Miehlke S, Schlag C, et al. Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial. Gastroenterology 2019;157: 74–86.e15.
72. Miehlke S, Hruz P, Vieth M, et al. A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis. Gut 2016;65:390–9. 73. Kahrilas PJ, Bredenoord AJ, Fox M, et al. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil 2015;27: 160–74.
74. Penagini R, Gyawali CP. Evaluation of esophageal contraction reserve using HRM in symptomatic esophageal disease. J Clin Gastroenterol 2019;53:322–30.
75. Ponds FA, Fockens P, Lei A, et al. Effect of peroral endoscopic myotomy vs pneumatic dilation on symptom severity and treatment outcomes among treatment-naive patients with achalasia: A randomized clinical trial. JAMA 2019;322:134–44.
76. Rex DK, Schoenfeld PS, Cohen J, et al. Quality indicators for colonoscopy. Gastroenterol Endosc 2015;81:31–53.
77. Jang JY, Chun HJ. Bowel preparations as quality indicators for colonoscopy. World J Gastroenterol 2014;20:2746–50.
78. Menees SB, Kim HM, Wren P, et al. Patient compliance and suboptimal bowel preparation with split-dose bowel regimen in average-risk screening colonoscopy. Gastrointest Endosc 2014;79:811–20.
79. Nguyen DL, Wieland M. Risk factors predictive of poor quality preparation during average risk colonoscopy screening: The importance of health literacy. J Gastrointestin Liver Dis 2010;19:369–72.
80. Johnson DA, Barkun AN, Cohen LB, et al. Optimizing adequacy of bowel cleansing for colonoscopy: Recommendations from the US Multi- Society Task Force on Colorectal Cancer. Gastroenterology 2014;147: 903–24.
81. Bucci C, Rotondano G, Hassan C, et al. Optimal bowel cleansing for colonoscopy: Split the dose! A series of meta-analyses of controlled studies. Gastrointest Endosc 2014;80:566–76.e562.
82. Kilgore TW, Abdinoor AA, Szary NM, et al. Bowel preparation with split-dose polyethylene glycol before colonoscopy: A meta-analysis of randomized controlled trials. Gastrointest Endosc 2011;73:1240–5.
83. Avalos DJ, Castro FJ, Zuckerman MJ, et al. Bowel preparations administered the morning of colonoscopy provide similar efficacy to a split-dose regimen: A meta analysis. J Clin Gastroenterol 2017;52: 859–68.
84. Lebwohl B, Wang TC, Neugut AI. Socioeconomic and other predictors of colonoscopy preparation quality. Dig Dis Sci 2010;55:2014–20.
85. Siddiqui AA, Yang K, Spechler SJ, et al. Duration of the interval between the completion of bowel preparation and the start of colonoscopy predicts bowel-preparation quality. Gastrointest Endosc 2009;69:700–6.
86. Kanth P, Grimmett J, Champine M, et al. Hereditary colorectal polyposis and cancer syndromes: A primer on diagnosis and management. Am J Gastroenterol 2017;112:1509–25.
87. Samadder NJ, Curtin K, Tuohy TM, et al. Increased risk of colorectal neoplasia among family members of patients with colorectal cancer: A population-based study in Utah. Gastroenterology 2014;147:814–21.
88. Samadder NJ, Smith KR, Hanson H, et al. Increased risk of colorectal cancer among family members of all ages, regardless of age of index case at diagnosis. Clin Gastroenterol Hepatol 2015;13:2305–11.
89. Leddin D, Lieberman DA, Tse F, et al. Clinical practice guideline on screening for colorectal cancer in individuals with a family history of nonhereditary colorectal cancer or adenoma: The Canadian Association of Gastroenterology Banff Consensus. Gastroenterology 2018;155: 1325–47.
90. Yurgelun MB, Kulke MH, Fuchs CS, et al. Cancer susceptibility gene mutations in individuals with colorectal cancer. J Clin Oncol 2017;35: 1086–95.
91. Valle L, Vilar E, Tavtigian SV, et al. Genetic predisposition to colorectal cancer: Syndromes, genes, classification of genetic variants and implications for precision medicine. J Pathol 2019;247:574–88.
92. AlDubayan SH, Giannakis M, Moore ND, et al. Inherited DNA-repair defects in colorectal cancer. Am J Hum Genet 2018;102:401–14.
93. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018;359:1350–5.
94. Ellis L, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract: Trends in incidence in England since 1971. Am J Gastroenterol 2010;105:2563–9.
95. Ducreux M, Ruszniewski P, Chayvialle JA, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000;95:3276–81.
96. Dillon JS, Kulke MH,H¨orsch D, et al. Time to sustained improvement in bowel movement frequency with telotristat ethyl: Analyses of phase III studies in carcinoid syndrome. J Gastrointest Cancer 2020 (doi:10.1007/ s12029-020-00375-2).
97. Hope TA, Abbott A, Colucci K, et al. NANETS/SNMMI procedure standard for somatostatin receptor-based peptide receptor radionuclide therapy with DOTATATE. J Nucl Med 2019;60:937–43.
98. MoonCM,Huh KC, Jung SA, et al. Long-term clinical outcomes of rectal neuroendocrine tumors according to the pathologic status after initial endoscopic resection: A kasid multicenter study. Am J Gastroenterol 2016;111:1276–85.
99. Rex DK, Schoenfeld PS, Cohen J, et al. Quality indicators for colonoscopy. Am J Gastroenterol 2015;110:72–90.
100. Lund M, Trads M, Njor SH, et al. Quality indicators for screening colonoscopy and colonoscopist performance and the subsequent risk of interval colorectal cancer: A systematic review. JBI Database Syst Rev Implement Rep 2019;17:2265–300.
101. ASGE Technology Committee; Trindade AJ, Lichtenstein DR, Aslanian HR, et al. Devices and methods to improve colonoscopy completion (with videos). Gastrointest Endosc 2018;87:625–34.
102. Murray JA, Van Dyke C, Plevak MF, et al. Trends in the identification and clinical features of celiac disease in a North American Community, 1950–2001. Clin Gastroenterol Hepatol 2003;1:19–27. 103. Choung RS, Unalp-AridaA, Ruhl CE, et al. Less hidden celiac disease but increased gluten avoidance without a diagnosis in the United States: Findings from the National Health and Nutrition Examination Surveys from 2009 to 2014. Mayo Clin Proc;S0025-6196(16)30634-6 (doi:10. 1016/j.mayocp.2016.10.012).
104. Rubio-Tapia A, Ludvigsson JF, Brantner TL, et al. The prevalence of celiac disease in the United States. Am J Gastroenterol 2012;107: 1538–44.
105. Vriezinga SL, Auricchio R, Bravi E, et al. Randomized feeding intervention in infants at high risk for celiac disease. N Engl J Med 2014; 371(14):1304–15.
106. Lionetti E, Castellaneta S, Francavilla R, et al. Introduction of gluten, HLA status, and the risk of celiac disease in children.NEngl J Med 2014; 371:1295–303.
107. Ludvigsson JF, Lebwohl B. Three papers indicate that amount of gluten play a role for celiac disease—But only a minor role. Acta Paediatr 2020; 109:8–10.
108. Shah S, Akbari M, Vanga R, et al. Patient perception of treatment burden is high in celiac disease compared with other common conditions. Am J Gastroenterol 2014;109:1304–11.
109. Lerner BA, Phan Vo LT, Yates S, et al. Detection of gluten in gluten-free labeled restaurant food: Analysis of crowd-sourced data. Am J Gastroenterol 2019;114:792–7.
110. Mukewar SS, Sharma A, Rubio-Tapia A, et al. Open-capsule budesonide for refractory celiac disease. Am J Gastroenterol 2017;112:959–67.
111. Leffler DA, Kelly CP, Green PHR, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: A randomized controlled trial. Gastroenterology 2015;148:1311–9.
112. Murray JA, Kelly CP, Green PHR, et al. No difference between latiglutenase and placebo in reducing villous atrophy or improving symptoms in patients with symptomatic celiac disease. Gastroenterology 2017;152:787–98.
113. Truitt KE, Daveson AJM, Ee HC, et al. Randomised clinical trial: A placebo-controlled study of subcutaneous or intradermalNEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease. Aliment Pharmacol Ther 2019;50:547–55.
114. Jeppesen PB, Pertkiewicz M, Messing B, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology 2012;143:1473.
115. Seidner DL, Fujioka K, Boullata JI, et al. Reduction of parenteral nutrition and hydration support and safety with long-term teduglutide treatment in patient with short bowel syndrome-associated intestinal failure: STEPS-3 study. Nutr Clin Pract 2018;33:520–7.
116. Kocoshis SA, Merritt RJ, Hill S, et al. Safety and efficacy of teduglutide in pediatric patients with intestinal failure due to short bowel syndrome: A 24-week, phase III study. JPEN J Parenter Enteral Nutr 2020;44:621–31.
117. Hvistendahl M, Brandt CF, Tribler S, et al. Effect of liraglutide treatment on jejunostomy output in patients with short bowel syndrome: An openlabel pilot study. JPEN J Parenter Enteral Nutr 2018;42:112–21.
118. Wismann P, Pedersen Sl, Hansen G, et al. Novel GLP-1/GLP-2 coagonists display marked effects on gut volume and improved glycemic control in mice. Physiol Behav 2018;192:72–81.
119. Drossman DA, Tack J, Ford AC, et al. Neuromodulators for functional gastrointestinal disorders (disorders of gut-brain interaction): A rome foundation working team report. Gastroenterology 2018;154:1140–71.
120. Mayer EA, Labus J, Aziz Q, et al. Role of brain imaging in disorders of brain-gut interaction: A rome working team report. Gut 2019;68: 1701–15.
121. Simren M, Tornblom H, Palsson OS, et al. Cumulative effects of psychologic distress, visceral hypersensitivity, and abnormal transit on patient-reported outcomes in irritable bowel syndrome. Gastroenterology 2019;157:391–402.e2.
122. Keefer L, Palsson OS, Pandolfino JE. Best practice update: Incorporating psychogastroenterology into management of digestive disorders. Gastroenterology 2018;154:1249–57.
123. Everitt HA, Landau S, O’Reilly G, et al. Assessing telephone-delivered cognitive-behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): A multicentre randomized trial. Gut 2019;68:1613–23.
124. Bonnert M, Olen O, Lalouni M, et al. Internet-delivered cognitive behavior therapy for adolescents with irritable bowel syndrome: A randomized controlled trial. Am J Gastroenterol 2017;112:152–62.
125. Lalouni M, Ljotsson B, Bonnert M, et al. Clinical and cost effectiveness of online cognitive behavioral therapy in children with functional abdominal pain disorders. Clin Gastroenterol Hepatol 2019;17: 2236–44.e11.
126. Lowen MB, Mayer EA, Sjoberg M, et al. Effect of hypnotherapy and educational intervention on brain response to visceral stimulus in the irritable bowel syndrome. Aliment Pharmacol Ther 2013;37: 1184–97.
127. Flik CE, Laan W, Zuithoff NPA, et al. Efficacy of individual and group hypnotherapy in irritable bowel syndrome (IMAGINE): A multicentre randomised controlled trial. Lancet Gastroenterol Hepatol 2019;4: 20–31.
128. Black CJ, Yuan Y, Selinger CP, et al. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: A systematic network meta-analysis. Lancet Gastroenterol Hepatol 2020;5:117–31.
129. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15:1655–66.
130. Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358: 2344–54.
131. Carbone F, Van den Houte K, Clevers E, et al. Prucalopride in gastroparesis: A randomized placebo-controlled crossover study. Am J Gastroenterol 2019;114:1265–74.
132. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: A 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012;107:1702–12.
133. Brenner DM, Fogel R, Dorn SD, et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: Results of two phase 3 randomized clinical trials. Am J Gastroenterol 2018;113:735–45.
134. Chey WD, Lembo A, Rosenbaum DP. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: A 12-week placebo-controlled phase 3 trial (T3MPO). Am J Gastroenterol 2020; 115:281–93.
135. Lembo AJ, Lacy BE, Zuckerman M, et al. Eluxadoline for irritable bowel syndrome with diarrhea. NEJM 2016;374:242–53.
136. Brenner DM, Sayuk GS, Gutman CR, et al. Efficacy and safety of eluxadoline in patients with irritable bowel syndrome with diarrhea who report inadequate symptom control with loperamide: RELIEF phase 4 study. Am J Gastroenterol 2019;114:1502–11.
137. Weerts ZZRM, Masclee AAM, Witteman BJM, et al. Efficacy and safety of peppermint oil in a randomized double-blind trial of patients with irritable bowel syndrome. Gastroenterology 2020;158:123–36.
138. Slattery SA, Niaz O, Aziz Q, et al. Systematic review with meta-analysis: The prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther 2015;42:3–11.
139. Sadowski DC, Camilleri M, Chey WD, et al. Canadian Association of Gastroenterology clinical practice guideline on the management of bile acid diarrhea. Clin Gastroenterol Hepatol 2020;18:24–41.
140. KlemF,WadhwaA, Prokop LJ, et al. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: A systematic review and meta-analysis. Gastroenterology 2017;152:1042–54.e1.
141. Futagami S, Itoh T, Sakamoto C. Systematic review with meta-analysis: Post-infectious functional dyspepsia. Aliment Pharmacol Ther 2015;41: 177–88.
142. Shah A, Talley NJ, Jones M, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: A systematic review and meta-analysis of case-control studies. Am J Gastroenterol 2020;115:190–201.
143. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. NEngl J Med 2011; 364:22–32.
144. Tan VP, Liu KS, Lam FY, et al. Randomised clinical trial: Rifaximin versus placebo for the treatment of functional dyspepsia. Aliment Pharmacol Ther 2017;45:767–76.
145. Fodor AA, Pimentel M, Chey WD, et al. Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome. Gut Microbes 2019;10:22–33.
146. Ford AC, Harris LA, Lacy BE, et al. Systematic review with metaanalysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther 2018;48:1044–60.
147. Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: Systematic review and meta-analysis. Am J Gastroenterol 2014;109:1547–61.
148. Osadchiy V, Martin CR, Mayer EA. The gut-brain axis and the microbiome: Mechanisms and clinical implications. Clin Gastroenterol Hepatol 2019;17:322–32.
149. Labus JS, Osadchiy V, Hsiao EY, et al. Evidence for an association of gut microbial Clostridia with brain functional connectivity and gastrointestinal sensorimotor function in patients with irritable bowel syndrome, based on tripartite network analysis. Microbiome 2019;7:45.
150. Pinto-Sanchez MI, Hall GB, Ghajar K, et al. Probiotic bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: A pilot study in patients with irritable bowel syndrome. Gastroenterology 2017;153:448–59.
151. Xu D, Chen VL, Steiner CA, et al. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: A systematic review and meta-analysis. Am J Gastroenterol 2019;114:1043–50.
152. El-Salhy M, Hatlebakk JG, Gilja OH, et al. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomized, double-blind, placebo-controlled study. Gut 2020;69: 859–67.
153. Ekekezie C, Perler BK, Wexler A, et al. Understanding the scope of do-ityourself fecal microbiota transplant. Am J Gastroenterol 2020;115: 603–7.
154. Dionne J, Ford AC, Yuan Y, et al. A systematic review and meta-analysis evaluating the efficacy of a gluten-free diet and a low FODMAPs diet in treating symptoms of irritable bowel syndrome. Am J Gastroenterol 2018;113:1290–300.
155. Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Short-term antiviral efficacy of BILIN 2-61, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004;127:1347–55.
156. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment -na¨ıve patients with genotype 1 hepatits C infection (SPRINT-1): An open label randomized, multicenter phase 2 trial. Lancet 2010;376:705–16.
157. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827–38.
158. Lawitz E, Mangia A, Wyles D, et al. Sofobuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2014;368:1878–87.
159. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-na¨ıve patients: The COSMOS Randomised study. Lancet 2014;384:1756–65.
160. Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015;373: 2599–607.
161. Foster GR, Afdhal N, Roberts SK. Sofosbuvir and velpatasivr for HCV genotype 2 and 3 infection. N Engl J Med 2015;373:2608–17.
162. Asselah T, Hezode C, Zadeikis N, et al. ENDURANCE-4: Efficacy and safety of glecaprevir/pibrentasvir (formerly ABT-493/ABT-530) treatment in patients with chronic HCV genotype 4, 5, or 6 infection. Hepatology 2016;64(Suppl 1):114.
163. Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks inHCVgenotype 1 or 3 infection.NEngl J Med 2018;378:354–69.
164. Backus LI, Belperio PS, Shahoumian TA, et al. Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease. Hepatology 2018;68:827–38.
165. Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: Observational study. BMJ 2018;362:k2817.
166. Singhal AK, Louvet A, Shah VH, et al. Grand rounds: Alcoholic hepatitis. J Hepatol 2018;69:534–43.
167. Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011;365:1790–800.
168. Lee BP, Mehta N, Platt L, et al. Outcomes of early liver transplantation for patients with severe alcoholic hepatitis. Gastroenterology 2018;155: 422–30.
169. Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. State-level prevalence of adult obesity and severe obesity. N Engl J Med 2019;381: 2440–50.
170. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73–84.
171. Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018;67:123–33.
172. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and metaanalysis. Hepatology 2017;65:1557–65.
173. Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 2015;62: 1723–30.
174. Kwong A, Kim WR, Lake JR, et al. OPTN/SRTR 2018 annual data report: Liver. Am J Transpl 2020;20(Suppl s1):193–299.
175. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328–57.
176. Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018;24: 908–22.
177. Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2019;394:2184–96.
178. Muller T, Beutler C, Pico AH, et al. Increased T help 2 cytokines in bile from patients with IgG4 related cholangitis disrupt the tight junction associated biliary epithelial cell barrier. Gastroenterology 2013;144: 1116–28.
179. Zen Y, Fujii T, Harada K, et al. Th2 and regulatory immune reactions are increased in immunoglobin G4 related sclerosing pancreatitis and cholangitis. Hepatology 2007;45:1538–46.
180. Sleznik GM, Reding T, Romrig F, et al. Lymphotoxin beta receptor signaling promotes development of autoimmune pancreatitis. Gastroenterology 2012;143:1361–74.
181. Schwaiger T, van den Brandt C, Fitzner B, et al. Autoimmune pancreatitis in MRL/Mp mice is a T cell-mediated disease responsive to cyclosporine A and rapamycin treatment. Gut 2014;63:494–505. 182. Sah RP, Chari ST, Pannala R, et al. Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology 2010;139:140–8.
183. Chari ST, Kloppen G, Zhang L, et al. Histologic and clinical subtypes of autoimmune pancreatitis: The Honolulu Consensus Document. Pancreas 2010;39:549–54.
184. Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: Guidelines of the International Association of Pancreatology. Pancreas 2011;40:352–8.
185. Kurita A, Yasukawa S, Zen Y, et al. Comparison of a 22-gauge franseentip needle with a 20-gauge forward-bevel for the diagnosis of type 1 autoimmune pancreatitis: A prospective, randomized, controlled, multicenter study (COMPAS study). Gastrointest Endosc 2020;91: 373–81.
186. Kazaki K, Chari ST, Frulloni, et al. International consensus for treatment of autoimmune pancreatitis. Pancreatology 2017;17:1–6.
187. Hart PA, Topazian MD, Witzig TE, et al. Treatment of refractory autoimmune pancreatitis with immunomodulators and Rituximab. The Mayo Clinic experience. Gut 2013;62:1607–15.
188. Masamune A, Nishimori I, Kikuta K, et al. Randomized controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis. Gut 2017;66:489–92.
189. Banks BA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis—2012: Revision of the Atlanta classification and definitions by international consensus. Gut 2013;62:102–11.
190. Siddiqui AA, Adler DG, Nieto J, et al. EUS-guided drainage of peripancreatic fluid collections and necrosis by using a novel lumenapposing stent: A large retrospective, multicenter U.S. Experience. Gastrointest Endosc 2016;83:699–707.
191. van Brunschot S, van Grinsven J, van Santvoort HC, et al. Endoscopic or surgical step-up approach for infected necrotising pancreatitis: A multicentre randomised trial. Lancet 2018;391:51–8.
192. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet 2018;390(10114):2769–78.
193. Kaplan GG. The global burden of IBD: From 2015 to 2025. Nat Rev Gastroenterol Hepatol 2015;12:720–7.
194. Kotze PG, Underwood FE, Damiao A, et al. Progression of inflammatory bowel diseases throughout Latin America and the Caribbean: A systematic review. Clin Gastroenterol Hepatol 2020;18:304–12.
195. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46–54.
196. Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology 2017;152:313–21.e312.
197. Coward S, Clement F, Benchimol EI, et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology 2019;156:1345–53.e1344.
198. Jones GR, Lyons M, Plevris N, et al. IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology. Gut 2019;68(11):1953–60.
199. Nguyen GC, Targownik LE, Singh H, et al. The impact of inflammatory bowel disease in Canada 2018: IBD in seniors. J Can Assoc Gastroenterol 2019;2(Suppl 1):S68–S72.
200. Ananthakrishnan AN, Kaplan GG, Ng SC. Changing global epidemiology of inflammatory bowel diseases: Sustaining health care delivery into the 21st century. Clin GastroenterolHepatol 2020;18(6): 1252–60.
201. Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol 2014;12:1246–56.e1246.
202. Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on crohn’s disease (CALM): A multicentre, randomised, controlled phase 3 trial. Lancet 2018;390:2779–89.
203. Borg-Bartolo SP, Boyapati RK, Satsangi J, et al. Precision medicine in inflammatory bowel disease: Concept, progress and challenges. F1000Res 2020;9:F1000 Faculty Rev-54. Published online 2020 Jan 28 (doi: 10.12688/f1000research.20928.1).
204. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: Management of crohn’s disease in adults. Am J Gastroenterol 2018;113: 481–517.
205. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: Ulcerative colitis in adults. Am J Gastroenterol 2019;114: 384–413.
206. Wong U, Cross RK. Primary and secondary nonresponse to infliximab: Mechanisms and countermeasures. Expert Opin Drug Metab Toxicol 2017;13:1039–46.
207. Na SY, Moon W. Perspectives on current and novel treatments for inflammatory bowel disease. Gut Liver 2019;13:604–16.